MEDICAL IP participated in the 'HIMSS 2024 Europe Health Conference & Exhibition' held in Rome, Italy, from May 29 to 31, where they introduced and demonstrated their software for liver cancer occurrence and recurrence risk assessment, DeepFore and DeepFore Recur. Additionally, they showcased their AI solution, MEDIP PRO, which automatically segments and models 3D medical images of the entire body, and MDBOX, a 3D medical imaging anatomical content designed for educational and training purposes.

MEDICAL IP is currently developing medical AI software for risk assessment of liver cancer occurrence and recurrence through the Dr. Answer 2.0 project, sponsored by the Ministry of Science and ICT and the National IT Industry Promotion Agency. DeepFore is a risk assessment software for predicting the occurrence of hepatocellular carcinoma in patients with hepatitis B, while DeepFore Recur assesses the risk of recurrence following curative treatment for hepatocellular carcinoma.

By using AI software to provide personalized liver cancer solutions, it is possible to detect hepatocellular carcinoma at an early stage. Depending on the risk of liver cancer occurrence and recurrence, customized hepatocellular carcinoma treatment plans can be established, potentially reducing unnecessary tests and lowering medical expenses for patients.

-Editor's Note-

[View Article]